KR101122483B1 - 항진균 활성을 갖는 트리아졸 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물 - Google Patents
항진균 활성을 갖는 트리아졸 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물 Download PDFInfo
- Publication number
- KR101122483B1 KR101122483B1 KR1020097012702A KR20097012702A KR101122483B1 KR 101122483 B1 KR101122483 B1 KR 101122483B1 KR 1020097012702 A KR1020097012702 A KR 1020097012702A KR 20097012702 A KR20097012702 A KR 20097012702A KR 101122483 B1 KR101122483 B1 KR 101122483B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- difluorophenyl
- triazol
- butan
- pyrazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Description
Claims (7)
- 하기 화학식 1의 화합물, 또는 이의 광학 이성질체 또는 약제학적으로 허용가능한 염:화학식 1상기 식에서,Ar은 하나 이상의 할로겐으로 치환된 페닐이고;R1은 C1-C4 알킬이며;R2, R3 및 R4는 서로 동일하거나 상이할 수 있으며, 각각 독립적으로 수소, 할로겐, 시아노, 니트로, C1-C4 알킬, C1-C4 할로알킬을 나타내고, 다만 R4는 상기한 치환기로부터 각각 독립적으로 동일하거나 상이하게 선택될 수 있는 둘 이상의 치환기일 수 있고;
- 제 1 항에 있어서,C1-C4 알킬은 메틸, 에틸, 프로필, 이소프로필, 부틸, 이소부틸, sec-부틸 또는 tert-부틸기이고;C1-C4의 할로알킬은 트리플루오로메틸, 트리클로로메틸, 플루오로메틸, 클로로메틸, 브로모메틸, 요오도메틸, 디플루오로메틸, 디클로로메틸, 2-클로로에틸, 2,2-디클로로에틸, 2,2,2-트리클로로에틸, 펜타클로로에틸, 2-플루오로에틸, 2,2-디플루오로에틸, 2,2,2-트리플루오로에틸, 펜타플루오로에틸, 3-클로로프로필, 3,3-디클로로프로필, 3,3,3-트리클로로프로필, 2,2,3,3,3-펜타클로로프로필, 3-플루오로프로필, 3,3-디플루오로프로필, 3,3,3-트리플루오로프로필, 2,2,3,3-테트라플루오로프로필, 2,2,3,3,3-펜타플루오로프로필, 헵타플루오로프로필, 4-클로로부틸, 4-플루오로부틸, 4-요오도부틸 또는 4-브로모부틸인 것을 특징으로 하는, 화학식 1의 화합물, 또는 이의 광학 이성질체 또는 약제학적으로 허용가능한 염.
- 삭제
- 제 1 항에 있어서,하기 화합물들로 이루어진 군에서 선택되는 것을 특징으로 하는, 화학식 1의 화합물, 또는 이의 광학 이성질체 또는 약제학적으로 허용가능한 염:1-(4-클로로페닐)-3-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H- 1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)이미다졸리딘-2-온 (화합물 1),4-((E)-2-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)비닐)벤조니트릴 (화합물 2),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-(4-플루오로벤질아미노)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 3),(2R,3R)-3-(4-(4-클로로벤질아미노)-1H-피라졸-1-일)-2-(2,4-디플루오로페닐)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 4),(2R,3R)-3-(4-(4-클로로페닐아미노)메틸)-1H-피라졸-1-일)-2-(2,4-디플루오로페닐)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 5),(2R,3R)-3-(4-(4-브로모페닐아미노)메틸)-1H-피라졸-1-일)-2-(2,4-디플루오로페닐)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 6),(2R,3R)-3-(4-(4-니트로페닐아미노)메틸)-1H-피라졸-1-일)-2-(2,4-디플루오로페닐)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 7),(2R,3R)-3-(4-(4-클로로페닐)(메틸)아미노)메틸)-1H-피라졸-1-일)-2-(2,4-디플루오로페닐)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 8),(2R,3R)-3-(4-(4-브로모페닐)(메틸)아미노)메틸)-1H-피라졸-1-일)-2-(2,4-디플루오로페닐)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 9),(2R,3R,E)-2-(2,4-디플루오로페닐)-3-(4-(4-플루오로벤질리덴아미노)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 10),N-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1- 일)부탄-2-일)-1H-피라졸-4-일)-4-플루오로벤즈아미드 (화합물 11),4-클로로-N-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)-벤즈아미드 (화합물 12),4-클로로-N-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)-N-메틸벤즈아미드 (화합물 13),N-(4-클로로페닐)-1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-N-메틸-1H-피라졸-4-카복사마이드 (화합물 14),(4-클로로페닐)-1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)메타논 (화합물 15),1-(4-클로로페닐)-2-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일아미노)에타논 (화합물 16),1-(2,2-디에톡시에틸)-1-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)-3-(4-플루오로페닐)우레아 (화합물 17),3-(4-클로로페닐)-1-(2,2-디에톡시에틸)-1-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)우레아 (화합물 18),1-(2,2-디에톡시에틸)-1-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)-3-(4-트리플루오로메틸)페닐)우레아 (화합물 19),3-(4-tert-부틸페닐)-1-(2,2-디에톡시에틸)-1-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)우레아 (화합물 20),3-(2,4-디클로로페닐)-1-(2,2-디에톡시에틸)-1-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)우레아 (화합물 21),1-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)-3-(4-플루오로페닐)-1H-이미다다졸-2(3H)-온 (화합물 22),3-(4-클로로페닐)-1-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)-1H-이미다졸-2(3H)-온 (화합물 23),1-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)-1H-3-(4-트리플루오로메틸)페닐)이미다졸-2(3H)-온 (화합물 24),3-(4-tert-부틸페닐)-1-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)-1H-이미다졸-2(3H)-온 (화합물 25),3-(2,4-디클로로페닐)-1-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)-1H-이미다졸-2(3H)-온 (화합 물 26),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-((4-(4-플루오로페닐)피페라진-1-일)메틸)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 27),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-((4-(4-니트로페닐)피페라진-1-일)메틸)-1H-피라졸-1-일)-1-(1H-1,2,4-프리아졸-1-일)부탄-2-올 (화합물 28),1-(4-클로로페닐)-4-((1-(2R,3R)-3-(3,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)메틸)피페라진-2-온 (화합물 29),(1-(2R,3R)-2-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)(4-(4-플루오로페닐)피페라진-1-일)메타논 (화합물 30),(4-(4-클로로페닐)피페라진-1-일)(1-((2R,3R)-2-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)메타논 (화합물 31),(1-(2R,3R)-2-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)(4-(4-니트로페닐)피페라진-1-일)메타논 (화합물 32),(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-N-(4-플루오로페닐)-5-메틸-1H-피라졸-4-카복사미드 (화합물 33),N-(4-클로로페닐)-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-5-메틸-1H-피라졸-4-카복사미드 (화합물 34),N-(4-클로로페닐)-1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H- 1,2,4-트리아졸-1-일)부탄-2-일)-N,5-디메틸-1H-피라졸-4-카복사미드 (화합물 35),(4-(4-클로로페닐)피페라진-1-일)(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-5-메틸-1H-피라졸-4-일)메타논 (화합물 36),(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-5-메틸-1H-피라졸-4-일)(4-(4-니트로페닐)피페라진-1-일)메타논 (화합물 37),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-(4-플루오로펜에틸)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 38),(2R,3R)-3-(4-(4-클로로펜에틸)-1H-피라졸-1-일)-2-(2,4-디플루오로페닐)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 39),(2R,3R,E)-2-(2,4-디플루오로페닐)-3-(4-(4-플루오로스티릴)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 40),(2R,3R,E)-3-(4-(4-클로로스티릴)-1H-피라졸-1-일)-2-(2,4-디플루오로페닐)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 41),(2R,3R,E)-2-(2,4-디플루오로페닐)-3-(4-(4-니트로스티릴)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 42),(2R,3R,E)-2-(2,4-리플루오로페닐)-3-(4-(4-트리플루오로메틸)스티릴)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 43),(2R,3R,E)-3-(4-(3,4-디클로로스티릴)-1H-피라졸-1-일)-2-(2,4-디플루오로페 닐)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 44),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-(4-플루오로페닐)에티닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 45),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-(2,4-디플루오로페닐)에티닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 46),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-(4-플루오로-3-메틸페닐)에티닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 47),4-((1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-(4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)에티닐)벤조니트릴 (화합물 48),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-(4-플루오로벤질)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 49),(2R,3R)-3-(4-(4-클로로벤질)-2-(2,4-디플루오로페닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 50),(2R,3R,E)-2-(2,4-디플루오로페닐)-3-(4-(2-(피리딘-2-일)비닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 51),(2R,3R,E)-2-(2,4-디플루오로페닐)-,3-(4-(2-(피리딘-3-일)비닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 52),(2R,3R,E)-2-(2,4-디플루오로페닐)-3-(4-(2-(피라진-2-일)비닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 53),(2R,3R,E)-2-(2,4-디플루오로페닐)-3-(4-(2-(6-메틸피리딘-2-일)비닐)-1H-피 라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 54),(2R,3R,E)-2-(2,4-디플루오로페닐)-3-(4-(2-(5-니트로피리딘-2-일)비닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 55),(2R,3R,E)-2-(2,4-디플루오로페닐)-3-(4-(2-(3-메틸-5-니트로피리딘-2-일)비닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 56),(2R,3R,E)-2-(2,4-디플루오로페닐)-3-(4-(2-(6-니트로피리딘-3-일)비닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 57),5-(((E)-2-(1-((2R,3R)-3-(2,4-디플루오로페닐)-3-히드록시-4-(1H-1,2,4-트리아졸-1-일)부탄-2-일)-1H-피라졸-4-일)비닐)니코티노니트릴 (화합물 58),(2R,3R,E)-3-(4-(2-(5-클로로피리딘-2-일)비닐)-1H-피라졸-1-일)-2-(2,4-디플루오로페닐)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 59),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-(피리딘-2-일에티닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 60),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-(피리딘-3-일에티닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 61),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-(5-리트로피리딘-2-일에티닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부한-2-올 (화합물 62),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-(6-니트로피리딘-3-일에티닐)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 63),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-(3-메틸-5-니트로피리딘-2-일에티닐)- 1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 64),(2R,3R)-3-(4-((5-클로로피리딘-2-일)에티닐)-1H-피라졸-1-일)-2-(2,4-디플루오로페닐)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 65),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-(퀴놀린-4-일)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 66),(2R,3R)-2-(2,4-디플루오로페닐)-3-(4-(퀴녹살린-3-일)-1H-피라졸-1-일)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 67), 및(2R,3R)-3-(4-(벤조퓨란-2-일)-1H-피라졸-1-일)-2-(2,4-디플루오로페닐)-1-(1H-1,2,4-트리아졸-1-일)부탄-2-올 (화합물 68).
- 하기 화학식 2의 화합물을 염기의 존재하에 하기 화학식 3의 화합물과 반응시켜 하기 화학식 4의 화합물을 제조하고, 이로부터 화학식 1의 화합물을 제조하는 것을 포함하는, 하기 화학식 1의 화합물의 제조방법:화학식 1화학식 2화학식 3화학식 4상기 식에서,Ar, A, B, D, E, G, X, R1, R2, R3 및 R4는 제 1 항에서 정의한 바와 같고, Y는 -NO2, -B(OH)2, -B(OC(CH3)2)2, -CHO, Cl, Br, I, -CH2Cl, -CH2Br, -CO2H,-NH2, -COCl, -CH=CH2 또는 -CE≡CH의 치환체이다.
- 제 5 항에 있어서,염기가 수소나트륨, 탄산칼륨 및 메톡시나트륨 중에서 선택되는 무기염기 또는 트리에틸아민 또는 1,8-디아자비시클로[5,4,0]운데크-7엔(DBU) 중에서 선택된 유기염기인 것을 특징으로 하는 방법.
- 제 1 항, 제 2 항 및 제 4 항 중 어느 한 항에 따른 화합물, 이의 광학 이성질체 또는 이의 약제학적으로 허용가능한 염을 포함하는, 진균성 감염 질병 치료용 약학 조성물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060139039 | 2006-12-29 | ||
KR1020060139039A KR20080062876A (ko) | 2006-12-29 | 2006-12-29 | 신규한 항진균성 트리아졸 유도체 |
PCT/KR2007/006961 WO2008082198A1 (en) | 2006-12-29 | 2007-12-28 | Antifungal triazole derivatives, method for the preparation thereof and pharmaceutical composition containing same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090088912A KR20090088912A (ko) | 2009-08-20 |
KR101122483B1 true KR101122483B1 (ko) | 2012-02-29 |
Family
ID=39588786
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060139039A KR20080062876A (ko) | 2006-12-29 | 2006-12-29 | 신규한 항진균성 트리아졸 유도체 |
KR1020097012702A KR101122483B1 (ko) | 2006-12-29 | 2007-12-28 | 항진균 활성을 갖는 트리아졸 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060139039A KR20080062876A (ko) | 2006-12-29 | 2006-12-29 | 신규한 항진균성 트리아졸 유도체 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8063229B2 (ko) |
EP (1) | EP2114904B1 (ko) |
JP (1) | JP5209642B2 (ko) |
KR (2) | KR20080062876A (ko) |
CN (1) | CN101573344B (ko) |
ES (1) | ES2433684T3 (ko) |
WO (1) | WO2008082198A1 (ko) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007070514A1 (en) | 2005-12-13 | 2007-06-21 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
RS58449B1 (sr) | 2007-06-13 | 2019-04-30 | Incyte Holdings Corp | Upotreba soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h- pirazol-1-il)-3-ciklopentilpropionitrila |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
AU2010249380B2 (en) | 2009-05-22 | 2015-08-20 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors |
EP3643312A1 (en) | 2009-05-22 | 2020-04-29 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
CN102985417B (zh) | 2010-03-10 | 2015-01-28 | 因塞特公司 | 作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物 |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
EA035981B1 (ru) | 2010-05-21 | 2020-09-09 | Инсайт Холдингс Корпорейшн | Композиция ингибитора jak для местного применения |
WO2012047762A2 (en) * | 2010-10-08 | 2012-04-12 | Amplyx Pharmaceuticals, Inc. | Antifungal agents |
TW201249845A (en) | 2010-11-19 | 2012-12-16 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
WO2012177986A2 (en) | 2011-06-22 | 2012-12-27 | Vyome Biosciences | Conjugate-based antifungal and antibacterial prodrugs |
HUE027461T2 (en) | 2011-07-13 | 2016-09-28 | Basf Agro Bv | Fungicide substituted 2- [2-haloalkyl-4- (phenoxyphenyl) -1- [1,2,4] triazol-1-yl-ethanol compounds |
IN2014CN00832A (ko) | 2011-07-15 | 2015-04-03 | Basf Se | |
CN103648281B (zh) | 2011-07-15 | 2016-05-25 | 巴斯夫欧洲公司 | 杀真菌的烷基取代的2-[2-氯-4-(4-氯苯氧基)苯基]-1-[1,2,4]三唑-1-基乙醇化合物 |
JP2014529594A (ja) | 2011-08-15 | 2014-11-13 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 殺菌性置換1−{2−シクリルオキシ−2−[2−ハロ−4−(4−ハロゲン−フェノキシ)−フェニル]−エチル}−1h−[1,2,4]トリアゾール化合物 |
UY34258A (es) | 2011-08-15 | 2013-02-28 | Basf Se | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-2-alquinil/alquenil-etil}-1h-[1,2,4]triazol sustituidos |
MX2014000824A (es) | 2011-08-15 | 2014-02-27 | Basf Se | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-alcoxi-3-metil-butil}-1h-[1,2,4]triazol sustituidos. |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CN102503901B (zh) * | 2011-10-27 | 2014-06-18 | 中国人民解放军南京军区联勤部药品仪器检验所 | 氮唑类抗真菌化合物及其制备方法和应用 |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
CN102796080B (zh) * | 2012-05-16 | 2016-04-06 | 中国人民解放军第二军医大学 | 一种新型氮唑类抗真菌化合物及其制备方法和应用 |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
CN113384545A (zh) | 2012-11-15 | 2021-09-14 | 因赛特公司 | 鲁索利替尼的缓释剂型 |
PL2934147T3 (pl) | 2012-12-20 | 2020-06-29 | BASF Agro B.V. | Kompozycje zawierające związki triazolowe |
PL3219707T3 (pl) | 2013-01-09 | 2020-01-31 | BASF Agro B.V. | Sposób wytwarzania podstawionych oksiranów i triazoli |
SI3489239T1 (sl) | 2013-03-06 | 2022-04-29 | Incyte Holdings Corporation | Postopki in intermediati za pripravo zaviralca JAK |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
CA2914583C (en) | 2013-06-04 | 2019-06-18 | Vyome Biosciences Pvt. Ltd. | Coated particles and compositions comprising same |
CA2915054A1 (en) | 2013-06-12 | 2014-12-18 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
RU2669997C2 (ru) | 2013-07-08 | 2018-10-17 | Басф Агро Б.В. | Композиции, содержащие триазольное соединение и биопестицид |
EA201690357A1 (ru) | 2013-08-07 | 2016-07-29 | Инсайт Корпорейшн | Лекарственные формы с замедленным высвобождением для ингибитора jak1 |
CN103387548B (zh) * | 2013-08-08 | 2015-05-20 | 中国人民解放军第四○四医院 | 1,2,3-三唑类抗真菌化合物及其制备方法和应用 |
CN103450162B (zh) * | 2013-08-08 | 2015-07-15 | 中国人民解放军第一○二医院 | 含有苯甲酰胺类结构的三氮唑醇类化合物及其制备方法和应用 |
CN106163526B (zh) | 2014-01-29 | 2021-07-23 | 维奥姆治疗有限公司 | 抗性痤疮的治疗 |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
WO2015144808A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations of an fgfr inhibitor and an igf1r inhibitor |
KR102479693B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | 조합물 |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
EA032078B1 (ru) | 2014-06-25 | 2019-04-30 | Басф Агро Б.В. | Пестицидные композиции |
BR112017009282A2 (pt) | 2014-11-07 | 2018-01-30 | Basf Se | misturas fungicidas, composição pesticida, métodos para controlar pragas fitopatogênicas, para melhorar a fitossanidade e para proteção de material de propagação de plantas contra pragas, e, material de propagação de plantas. |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
CN104817508B (zh) * | 2015-03-10 | 2017-12-05 | 中国人民解放军第二军医大学 | 一种三氮唑醇类衍生物及其制备方法和应用 |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
LT3353177T (lt) | 2015-09-23 | 2020-08-25 | Janssen Pharmaceutica Nv | Tricikliniai heterociklai, skirti vėžio gydymui |
MX2018003564A (es) | 2015-09-23 | 2018-06-18 | Janssen Pharmaceutica Nv | 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer. |
BR112018068695B1 (pt) | 2016-03-16 | 2022-12-27 | Basf Se | Uso de um composto e método para controlar fungos fitopatogênicos |
BR112018068705B1 (pt) | 2016-03-16 | 2022-09-06 | Basf Se | Método para controlar fungos fitopatogênicos |
US10905122B2 (en) | 2016-03-16 | 2021-02-02 | Basf Se | Use of tetrazolinones for combating resistant phytopathogenic fungi on cereals |
CN106588889B (zh) * | 2016-11-25 | 2019-01-22 | 江苏恒盛药业有限公司 | 一种伏立康唑的制备方法 |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
SI3746429T1 (sl) | 2018-01-30 | 2023-01-31 | Incyte Corporation | Postopki za pripravo (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona) |
WO2019191684A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
CN110885323A (zh) * | 2019-12-02 | 2020-03-17 | 中国人民解放军第二军医大学 | 一种三氮唑醇类衍生物、其制备方法及应用 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2022206862A1 (zh) * | 2021-03-30 | 2022-10-06 | 上海济煜医药科技有限公司 | 双环类化合物的制备方法及作为抗菌剂的应用 |
CN113929660B (zh) * | 2021-10-18 | 2022-10-04 | 深圳市海滨制药有限公司 | 一种环氧乙烷衍生物开环方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0659751A1 (en) * | 1993-12-22 | 1995-06-28 | Takeda Chemical Industries, Ltd. | Optically active azole derivatives, their production and use |
KR950032186A (ko) * | 1994-02-07 | 1995-12-20 | 야시로 쥰지로 | 항진균제, 그의 제조 방법 및 중간체 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3313073A1 (de) * | 1983-04-12 | 1984-10-18 | Bayer Ag, 5090 Leverkusen | 1-azolyl-3-pyrazolyl-2-propanol-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide |
TW212798B (ko) | 1991-11-25 | 1993-09-11 | Takeda Pharm Industry Co Ltd | |
JP3415865B2 (ja) * | 1991-11-25 | 2003-06-09 | 武田薬品工業株式会社 | 光学活性アゾール化合物およびその用途 |
JPH069624A (ja) * | 1992-06-24 | 1994-01-18 | Ikeda Mohandou:Kk | トリアゾール誘導体 |
JP3452213B2 (ja) * | 1994-07-05 | 2003-09-29 | エーザイ株式会社 | 抗真菌剤及びその製造方法 |
JP3635686B2 (ja) * | 1994-08-10 | 2005-04-06 | エーザイ株式会社 | 抗真菌剤及びその製造方法 |
US6319933B1 (en) * | 2000-04-17 | 2001-11-20 | Basilea Pharmaceutica Ag | Azole derivatives |
JP2006151812A (ja) | 2003-01-30 | 2006-06-15 | Meiji Seika Kaisha Ltd | 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤 |
DE602005027595D1 (de) * | 2004-11-08 | 2011-06-01 | Toyota Technical Ct Usa Inc | System und verfahren für drahtlose kommunikation eines fahrzeuges |
US7812045B2 (en) * | 2005-03-30 | 2010-10-12 | Daewoong Pharmaceutical Co., Ltd. | Antifungal triazole derivatives |
US7968579B2 (en) * | 2005-10-31 | 2011-06-28 | Daewoong Pharmaceutical Co., Ltd. | Antifungal triazole derivatives |
-
2006
- 2006-12-29 KR KR1020060139039A patent/KR20080062876A/ko unknown
-
2007
- 2007-12-28 ES ES07851825T patent/ES2433684T3/es active Active
- 2007-12-28 WO PCT/KR2007/006961 patent/WO2008082198A1/en active Application Filing
- 2007-12-28 US US12/520,945 patent/US8063229B2/en not_active Expired - Fee Related
- 2007-12-28 CN CN200780048598XA patent/CN101573344B/zh active Active
- 2007-12-28 KR KR1020097012702A patent/KR101122483B1/ko active IP Right Grant
- 2007-12-28 JP JP2009543956A patent/JP5209642B2/ja not_active Expired - Fee Related
- 2007-12-28 EP EP07851825.5A patent/EP2114904B1/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0659751A1 (en) * | 1993-12-22 | 1995-06-28 | Takeda Chemical Industries, Ltd. | Optically active azole derivatives, their production and use |
KR950032186A (ko) * | 1994-02-07 | 1995-12-20 | 야시로 쥰지로 | 항진균제, 그의 제조 방법 및 중간체 |
Also Published As
Publication number | Publication date |
---|---|
US20100063285A1 (en) | 2010-03-11 |
CN101573344A (zh) | 2009-11-04 |
JP2010514760A (ja) | 2010-05-06 |
EP2114904A1 (en) | 2009-11-11 |
KR20080062876A (ko) | 2008-07-03 |
US8063229B2 (en) | 2011-11-22 |
EP2114904A4 (en) | 2010-07-21 |
WO2008082198A1 (en) | 2008-07-10 |
EP2114904B1 (en) | 2013-08-21 |
CN101573344B (zh) | 2013-03-27 |
JP5209642B2 (ja) | 2013-06-12 |
ES2433684T3 (es) | 2013-12-12 |
KR20090088912A (ko) | 2009-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101122483B1 (ko) | 항진균 활성을 갖는 트리아졸 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물 | |
JP5055263B2 (ja) | 抗真菌性トリアゾール誘導体 | |
US6750230B2 (en) | Pyrazole derivatives | |
US9359350B2 (en) | Ring-fused compound | |
KR100998816B1 (ko) | 신규한 항진균성 트리아졸 유도체 | |
PL217629B1 (pl) | Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie | |
CA2677736A1 (en) | Fused ring compounds as partial agonists of ppar-gamma | |
US7973056B2 (en) | Triazole derivative or salt thereof | |
WO2009128661A2 (ko) | 신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도 | |
WO2021243480A1 (zh) | 三唑磺酰胺类衍生物及其制备方法和应用 | |
AU2004200420A1 (en) | Inhibitor of cyclooxygenase | |
ES2305563T3 (es) | Derivados de pirazol y su uso como agentes terapeuticos para enfermedades mediadas por el vih. | |
US20040106612A1 (en) | 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | |
US20040110816A1 (en) | Pyrazole derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140306 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150306 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160329 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170403 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180404 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190402 Year of fee payment: 9 |